A proteogenomic view of Parkinson’s disease causality and heterogeneity
Sergio Kaiser,Luqing Zhang,Brit Mollenhauer,Jaison Jacob,Jaison Jacob,Simonne Longerich,Jorge Del-Aguila,Jacob Marcus,Neha Raghavan,David Stone,Olumide Fagboyegun,Douglas Galasko,Mohammed Dakna,Bilada Bilican,Bilada Bilican,Mary Dovlatyan,Anna Kostikova,Jingyao Li,Brant Peterson,Brant Peterson,Michael Rotte,Vinicius Sanz,Tatiana Foroud,Samantha J. Hutten,Mark Frasier,Hirotaka Iwaki,Andrew Singleton,Ken Marek,Karen Crawford,Fiona Elwood,Fiona Elwood,Mirko Messa,Mirko Messa,Pablo Serrano-Fernandez
DOI: https://doi.org/10.1038/s41531-023-00461-9
2023-02-11
Abstract:The pathogenesis and clinical heterogeneity of Parkinson’s disease (PD) have been evaluated from molecular, pathophysiological, and clinical perspectives. High-throughput proteomic analysis of cerebrospinal fluid (CSF) opened new opportunities for scrutinizing this heterogeneity. To date, this is the most comprehensive CSF-based proteomics profiling study in PD with 569 patients (350 idiopathic patients, 65 GBA + mutation carriers and 154 LRRK2 + mutation carriers), 534 controls, and 4135 proteins analyzed. Combining CSF aptamer-based proteomics with genetics we determined protein quantitative trait loci (pQTLs). Analyses of pQTLs together with summary statistics from the largest PD genome wide association study (GWAS) identified 68 potential causal proteins by Mendelian randomization. The top causal protein, GPNMB, was previously reported to be upregulated in the substantia nigra of PD patients. We also compared the CSF proteomes of patients and controls. Proteome differences between GBA + patients and unaffected GBA + controls suggest degeneration of dopaminergic neurons, altered dopamine metabolism and increased brain inflammation. In the LRRK2 + subcohort we found dysregulated lysosomal degradation, altered alpha-synuclein processing, and neurotransmission. Proteome differences between idiopathic patients and controls suggest increased neuroinflammation, mitochondrial dysfunction/oxidative stress, altered iron metabolism and potential neuroprotection mediated by vasoactive substances. Finally, we used proteomic data to stratify idiopathic patients into “endotypes”. The identified endotypes show differences in cognitive and motor disease progression based on previously reported protein-based risk scores.Our findings not only contribute to the identification of new therapeutic targets but also to shape personalized medicine in CNS neurodegeneration.
neurosciences